Actuate Therapeutics Q2 EPS $(0.30) Beats $(0.32) Estimate

Actuate Therapeutics (NASDAQ: ACTU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 4.76 percent. This is a 92.86 percent increase over losses of $(4.20) per share from the same period last year.